The role of monoamine oxidase inhibitors in current psychiatric practice

Jess G. Fiedorowicz, Karen L. Swartz

Research output: Contribution to journalReview articlepeer-review

93 Scopus citations


The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the past several decades with the expansion of psychiatrists' pharmacologic armamentarium. This trend has also been driven by concern about food and drug interactions and side effects, as well as waning physician experience with these medications. Many psychiatrists, in fact, never prescribe MAOIs. Recent research has liberalized the MAOI diet and identified symptom presentations more likely to respond to these medications. Thus, clinicians must continue to familiarize themselves with the properties of and indications for prescribing MAOIs.

Original languageEnglish (US)
Pages (from-to)239-248
Number of pages10
JournalJournal of psychiatric practice
Issue number4
StatePublished - Jul 2004


  • Atypical depression
  • Bipolar depression
  • Dosage
  • Drug response
  • Isocarboxazid
  • Major depression
  • Moclobemide
  • Monoamine oxidase inhibitors (MAOIs)
  • Phenelzine
  • Physician prescribing practices
  • Psychopharmacology
  • Selegiline
  • Tranylcypromine

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'The role of monoamine oxidase inhibitors in current psychiatric practice'. Together they form a unique fingerprint.

Cite this